TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9159724
Drug: Nonspecific psychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonspecific psychological treatment (control) for 10 weeks
Study: 9159724
Drug: Nonspecific psychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonspecific psychological treatment (control)
Study: 8292465
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg quinapril
Study: 8292465
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg quinapril
Study: 3541830
Drug: Imipramine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (up to 5 mg/kg/d)
Study: 3541830
Drug: Weight-corrected imipramine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-corrected imipramine dosage
Study: 31910896
Drug: Freeze-dried formulation
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze-dried formulation of Tamalakyadi decoction
Study: 31910896
Drug: Antihistamine loratadine
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antihistamine loratadine (control)
Study: 27977600
Drug: Sufentanil 2.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 2.0 μg/kg + dexmedetomidine 2.0 μg/kg (group S2)
Study: 27977600
Drug: Butorphanol 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 0.15 mg/kg + dexmedetomidine 2.0 μg/kg (group N2)
Study: 27977600
Drug: Butorphanol 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butorphanol 0.15 mg/kg + dexmedetomidine 1.5 μg/kg (group N1)
Study: 27977600
Drug: Sufentanil 2.0 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 2.0 μg/kg + dexmedetomidine 1.5 μg/kg (group S1)
Study: 23624699
Drug: Topical APF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical APF gel (1.23 % F, pH 3.5, for 4 min)
Study: 23624699
Drug: Fluoride +
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride + laser group (F + L)
Study: 20075768
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment for both DS and SPS
Study: 15533612
Drug: Dietary advice
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary advice to eat more oil-rich fish or take LCn3 supplements
Study: 12812661
Drug: Calmette‐Guerin vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calmette‐Guerin vaccine (BCG) once a week for 8 weeks and then once every month for 8 months
Study: 11061615
Drug: BIP +
Normalized name: Buprenorphine and Naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BIP + RT (bleomycin 30 units/24‐hour infusion, ifosfamide 5 g/m2/24 hours, cisplatin 50 mg/m2 followed by pelvic radiotherapy)
Study: 9293972
Drug: Captopril (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (mean dose 46/69 mg/day after 7 days/4 weeks)
Study: 23768518
Drug: Mega-dose vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mega-dose vitamin A supplementation (MVAS) of 60 mg administered at diagnosis and again after 1 month.
Study: 23322206
Drug: FLOT (infusional
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLOT (infusional 5-FU, leucovorin, oxaliplatin, and docetaxel 50 mg/m²)
Study: 20626444
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of a gel containing allium cepa, allantoin, and pentaglycan twice a day for 24 weeks
Study: 20626444
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical treatments
Study: 16508264
Drug: 36% phosphoric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36% phosphoric acid gel for 1 min
Study: 16508264
Drug: 36% phosphoric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36% phosphoric acid gel for 4 min
Study: 12953945
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum 299v in combination with metronidazole
Study: 12953945
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with metronidazole
Study: 14564593
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: low loading dose and high demand bolus
Study: 14564593
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: high loading dose and demand bolus
Study: 14564593
Drug: Group 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: high loading dose and low demand bolus
Study: 6365104
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg tulobuterol
Study: 6365104
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg fenoterol
Study: 30879366
Drug: Continuous probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous probiotics (1 capsule daily for 6 weeks after 7 days of clindamycin 2% vaginal cream)
Study: 30879366
Drug: Interrupted probiotics
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interrupted probiotics (1 capsule twice a week for 6 weeks after 7 days of clindamycin 2% vaginal cream)
Study: 19770374
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (cisplatin and fluorouracil)
Study: 15307543
Drug: Molecular Adsorbent
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular Adsorbent Recirculating System (MARS) for 3 consecutive days; continued if bilirubin > 6 mg/dl
Study: 15307543
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (non-MARS group)
Study: 9052301
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (2 mg) plus ketamine (60 mg) administered preoperatively (Group 1)
Study: 9052301
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (2 mg) plus ketamine (60 mg) administered postoperatively (Group 2)
Study: 8110072
Drug: rh‐EPO treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rh‐EPO treatment for 12 months
Study: 8110072
Drug: rh‐EPO treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rh‐EPO treatment for 24 months
Study: 19058926
Drug: Sustained release
Normalized name: Sustained Release Buccal Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained release (SR) methamphetamine (30 mg first pill, 1x/day; 0mg 5x/day)
Study: 16825088
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin E therapy (400 mg daily for 5 weeks)
Study: 12881929
Drug: 0.18 g
Normalized name: MENTHOL 0.18 g in 100 TOPICAL GRANULE [Cough Drops]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.18 g sucrose
Study: 12881929
Drug: 0.24 g
Normalized name: Sodium Fluoride 0.24 g in 100 g DENTAL PASTE [AM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.24 g sucrose (2 mL 12% sucrose)
Study: 7857509
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg dried hypericum extract
Study: 7857509
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg dried hypericum extract
Study: 7857509
Drug: 1800 mg
Normalized name: glycerin 1800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1800 mg dried hypericum extract
Study: 7857509
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 300 mg/day long-term dosing
Study: 7857509
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose pharmacokinetics
Study: 7857509
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of absorption lag-time
Study: 26341759
Drug: Walk-and-eat intervention
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walk-and-eat intervention (n = 30; nurse-supervised walking three times per week and weekly nutritional advice)
Study: 9504568
Drug: Interferon-gamma (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-gamma (100 microg) daily by subcutaneous injection for up to 90 days
Study: 8070510
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg naftopidil
Study: 24872875
Drug: Individualized manual
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized manual therapy and rehabilitative exercise
Study: 22669400
Drug: Continuous intradermal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intradermal absorbable sutures (A)
Study: 12794785
Drug: Operant pain
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operant pain treatment group (OTG; n = 40)
Study: 12794785
Drug: Standardized medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized medical program with emphasis on physical therapy (PTG; n = 21)
Study: 10808734
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (two-week treatment)
Study: 10808734
Drug: 5-mononitrate 40
Normalized name: Iso-5-mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-mononitrate 40 mg daily for two weeks
Study: 10808734
Drug: Propranolol (two-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (two-week therapy)
Study: 10808734
Drug: Nadolol 40-80
Normalized name: nadolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 40-80 mg daily for two weeks
Study: 2005691
Drug: Intravesical BCG
Normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical BCG (50 mg weekly for 6 weeks, at 8, 10, and 12 weeks, at 6 months and every 6 months thereafter)
Study: 2005691
Drug: Intravesical plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical plus percutaneous BCG (50 mg intravesical BCG weekly for 6 weeks, at 8, 10, and 12 weeks, at 6 months and every 6 months thereafter)
Study: 24610312
Drug: St John's
Normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
Approvals — FDA: no, EMA: no, PMDA: no
Description: St John's wort (SJW) co-administered with boceprevir
Study: 22460142
Drug: Tofacitinib 1
Normalized name: tofacitinib 11 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 1 mg
Study: 20149584
Drug: Ginger extract
Normalized name: ginger extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger extract (120 mg)
Study: 20149584
Drug: Control (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (1 g of coconut oil as placebo)
Study: 18497189
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health promotion program (tooth brushing 2 times/day, use of fluoridated toothpastes, dental care visits)
Study: 15812606
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) in combination with fluvoxamine
Study: 15812606
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) in combination with placebo
Study: 15812606
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) in combination with fluvoxamine or placebo
Study: 12420344
Drug: Chitosan (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan (750 mg pure chitosan per tablet, two tablets three times daily before each main meal)
Study: 12420344
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical placebo tablets)
Study: 7653757
Drug: Vecuronium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.3 mg administered into the systemic circulation at 10% recovery (Group 2)
Study: 7653757
Drug: Vecuronium 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vecuronium 0.3 mg given when twitch height recovered to 50% depression (Group 3)
Study: 1952297
Drug: Pentigetide nasal
Normalized name: pentigide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentigetide nasal solution (1 mg into each nostril four times daily)
Study: 1952297
Drug: Pentigetide nasal
Normalized name: pentigide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentigetide nasal solution
Study: 6820917
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of MMC immediately after operation
Study: 6820917
Drug: Futraful for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Futraful for one year after MMC administration
Study: 6820917
Drug: Futraful (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Futraful (dosage increase)
Study: 6820917
Drug: MMC and
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMC and futraful combination
Study: 20601741
Drug: BCAA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA supplementation (isoleucine:leucine:valine = 1:2.3:1.2) at 100 mg/kg body weight
Study: 20601741
Drug: Placebo (dextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (dextrin at 100 mg/kg body weight)
Study: 8960576
Drug: L-NMMA administration
Normalized name: L-NMMA
DrugBank: Tilarginine (DB11815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA administration
Study: 8251721
Drug: 100ml Naoxuenin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100ml Naoxuenin (NXN) oral liquid with conventional treatment
Study: 8251721
Drug: Current conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current conventional treatment
Study: 3762902
Drug: Lysine vasopressin
Normalized name: Lysine vasopressin
DrugBank: Lypressin (DB14642)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lysine vasopressin (0.4 ml, 23 IU per day in 3 divided doses for 15 days)
Study: 3762902
Drug: Desmopressin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin (0.2 ml, 20 micrograms per day in a single dose for 15 days)
Study: 3762902
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered by nasal route)
Study: 29087796
Drug: Mouthwash prepared
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthwash prepared from Pomegranate extract, 15 ml twice a day
Study: 29087796
Drug: Mouthwash prepared
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthwash prepared from Grape seed extract, 15 ml twice a day
Study: 29087796
Drug: Mouthwash prepared
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mouthwash prepared from Guava extract, 15 ml twice a day
Study: 29087796
Drug: Control -
Normalized name: HISTAMINE 6 mg in 1 mL PERCUTANEOUS INJECTION [Positive Skin Test Control - Histamine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control - Distil water, twice a day
Study: 27581531
Drug: Monitoring group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitoring group (oral prasugrel 5 mg daily with dose or drug adjustment)
Study: 27581531
Drug: Conventional group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional group (oral prasugrel 5 mg daily with no monitoring or treatment adjustment)
Study: 20034605
Drug: AS03(A)-adjuvanted H1N1
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03(A)-adjuvanted H1N1 vaccine containing 5.25 microg haemagglutinin (HA)
Study: 20034605
Drug: Non-adjuvanted H1N1
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted H1N1 vaccine containing 21 microg HA
Study: 20034605
Drug: AS03(A)-adjuvanted H1N1
Normalized name: AS03 Adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS03(A)-adjuvanted H1N1 vaccine
Study: 20034605
Drug: Non-adjuvanted H1N1
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted H1N1 vaccine
Study: 17697209
Drug: AT-1001 (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT-1001 (12 mg)
Study: 11852667
Drug: Pravastatin 10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin 10-20 mg/day for 12 weeks
Study: 7780090
Drug: 12 months
Normalized name: Elecare HMO 0-12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months of chemotherapy with rifampicin-isoniazid-ethambutol (ethambutol only for the first 6 months)
Study: 7780090
Drug: 18 months
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 18 months of chemotherapy with rifampicin-isoniazid-ethambutol (ethambutol only for the first 6 months)
Study: 30760581
Drug: Fevipiprant (DP2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fevipiprant (DP2 antagonist)
Study: 25073598
Drug: Autologous PRP
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous PRP therapy combined with a rehabilitation program
Study: 25073598
Drug: Autologous PRP
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous PRP therapy
Study: 22173851
Drug: Caffeine alone
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine alone (2.0 mg/kg)
Study: 22173851
Drug: Alcohol alone
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alcohol alone (0.6 g/kg)
Study: 15970291
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (Raloxifene, Estradiol valerate plus dienogest, Soy isoflavones)
Study: 9468233
Drug: Amitriptyline 50
Normalized name: amitriptyline 50 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 50 mg taken at bedtime
Study: 28634822
Drug: EPA (1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA (1800 mg/day)
Study: 26445565
Drug: Turkish coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turkish coffee (3 mg·kg(‐1) BW of caffeine)
Study: 19425467
Drug: Glyconutritional supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glyconutritional supplement
Study: 15745291
Drug: Passive continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive continuous infusion by gravitational force (Group 1)
Study: 15745291
Drug: Manually controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manually controlled pressure bag infusion at about 40 mmHg (Group 2)
Study: 12227872
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide (Triaz 6% special gel), applied twice daily for 14 days
Study: 12227872
Drug: Clindamycin (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin (1% clindamycin phosphate in Cleocin-T lotion), applied twice daily for 14 days
Study: 9231932
Drug: Toremifene (TOR)
DrugBank: Toremifene (DB00539)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Toremifene (TOR) 60 mg daily
Study: 8280654
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 40 mg daily
Study: 3307390
Drug: Peripheral iv
Normalized name: Soluline 7-Day Peripheral IV Line Supply
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral iv infusion of a 900 mosmol amino acid-glucose solution (2 L/day) for 21 days
Study: 11680575
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ribavirin/day (group A)
Study: 11680575
Drug: 1,000-1,200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000-1,200 mg ribavirin/day (group B)
Study: 29150328
Drug: AAFP 500mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAFP 500mg daily plus 4mg methylprednisolone BID
Study: 29150328
Drug: OAA 1000mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: OAA 1000mg daily plus 5mg prednisone BID
Study: 26458911
Drug: CogniPlus training
Approvals — FDA: no, EMA: no, PMDA: no
Description: CogniPlus training (20 sessions, twice a week)
Study: 26458911
Drug: Physical training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical training (30 min daily for 10 weeks)
Study: 19688282
Drug: Occupational therapy-led
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy-led lifestyle intervention
Study: 8610286
Drug: Pericardial closure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pericardial closure with PHB patch
Study: 8610286
Drug: No pericardial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pericardial patch (control group)
Study: 1782306
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg b.d.
Study: 1782306
Drug: Famotidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine (20 mg) b.d.
Study: 24306134
Drug: Alcohol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (0.8 g/kg for males, 0.75 g/kg for females)
Study: 19683086
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose given 5 years post-primary vaccination (Group Y5)
Study: 19683086
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose given 10 years post-primary vaccination (Group Y10)
Study: 28079517
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination (FDC) of candesartan and rosuvastatin
Study: 28079517
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of candesartan and rosuvastatin
Study: 10065905
Drug: Antipsychotic drugs
Normalized name: Diazepines, oxazepines, thiazepines and oxepines antipsychotic drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic drugs (neuroleptics, major tranquillizers)
Study: 7909402
Drug: Best 'drug'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best 'drug' therapy (class I or class III antiarrhythmic therapy)